Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03518060
Registration number
NCT03518060
Ethics application status
Date submitted
26/04/2018
Date registered
8/05/2018
Date last updated
16/10/2024
Titles & IDs
Public title
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
Query!
Scientific title
Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Query!
Secondary ID [1]
0
0
208982
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
JUNGLE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV Infections
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Acquired immune deficiency syndrome (AIDS / HIV)
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Drugs - JULUCA
Participants who received JULUCA - Virologically suppressed HIV positive participants, on a stable antiretroviral regimen, who switched to the 2-Drug Regimen JULUCA (Dolutegravir \[DTG\] / Rilpivirine \[RPV\]) were included in the study. Participants were followed-up for approximately 3 years during routine clinical practice.
Treatment: Drugs: JULUCA
JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Sustained Virologic Suppression at Year 3
Query!
Assessment method [1]
0
0
Virologic suppression (VS) was defined as HIV-RNA less than (\<) 50 copies (c)/mL for at least 6 months or, if between 50-200 c/mL with a subsequent next available measurement (within 120 days) \<50 c/mL at Year 3 follow-up. Any subsequent measurement was accepted as a consecutive measurement as long as measured no later than 120 days after the initial measurement. If no subsequent HIV-RNA measurement was performed within 120 days, this was scored as a confirmed HIV-RNA greater than or equal to (\>=)200 c/mL.
Query!
Timepoint [1]
0
0
At Year 3
Query!
Secondary outcome [1]
0
0
Number of Participants With Sustained Virologic Suppression at Year 1 and Year 2
Query!
Assessment method [1]
0
0
VS was defined as HIV-RNA \<50 c/mL for at least 6 months or, if between 50-200 c/mL with a subsequent next available measurement (within 120 days) \<50 c/mL. Any subsequent measurement was accepted as a consecutive measurement as long as measured no later than 120 days after the initial measurement. If no subsequent HIV-RNA measurement was performed within 120 days, this was scored as a confirmed HIV-RNA \>=200 c/mL.
Query!
Timepoint [1]
0
0
At Year 1 and Year 2
Query!
Secondary outcome [2]
0
0
Number of Participants With Low Level Viremia
Query!
Assessment method [2]
0
0
Low level viremia was defined as a VL greater than (\>) 50 to \<200 c/mL.
Query!
Timepoint [2]
0
0
At Year 1, Year 2 and Year 3
Query!
Secondary outcome [3]
0
0
Number of Participants With Virologic Rebound
Query!
Assessment method [3]
0
0
Virologic rebound was defined as two consecutive VL measurements of \>=200 c/mL.
Query!
Timepoint [3]
0
0
At Year 1, Year 2 and Year 3
Query!
Secondary outcome [4]
0
0
Number of Participants With Treatment Switch
Query!
Assessment method [4]
0
0
The treatment switch could have been due to virologic failure (VF) or due to intolerability and last observation carried forward (LOCF) as determined at the discretion of the physician.
Query!
Timepoint [4]
0
0
At Year 1, Year 2 and Year 3
Query!
Secondary outcome [5]
0
0
Number of Monitoring Measures During the 3-year Follow-up
Query!
Assessment method [5]
0
0
The HIV monitoring measures included were defined as HIV-RNA measurements, normalized to participant years.
Query!
Timepoint [5]
0
0
Up to Year 3
Query!
Secondary outcome [6]
0
0
Number of Participants With Serious Adverse Events (SAEs)
Query!
Assessment method [6]
0
0
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal investigational product, whether or not related to the medicinal investigational product. A SAEs was defined as any adverse event meeting the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a congenital anomaly in the off-spring of a participant, was medically significant or could have required intervention to prevent the previously stated outcomes.
Query!
Timepoint [6]
0
0
Up to Year 3
Query!
Secondary outcome [7]
0
0
Number of Participants With Adverse Drug Reactions (ADRs)
Query!
Assessment method [7]
0
0
An ADR was defined as a noxious and unintended response to a medicinal investigational product related to any dose where at least a reasonable possibility (i.e. the relationship) cannot be ruled out.
Query!
Timepoint [7]
0
0
Up to Year 3
Query!
Secondary outcome [8]
0
0
Number of Participants With Adherence to Therapy
Query!
Assessment method [8]
0
0
Adherence to therapy refers to the missed monthly doses. At each follow-up visit, participants were asked to give an estimation of their level of adherence to their antiretroviral therapy (ART).
Query!
Timepoint [8]
0
0
At Year 1, Year 2 and Year 3
Query!
Secondary outcome [9]
0
0
Change From Baseline (BL) in Lipid Laboratory Values
Query!
Assessment method [9]
0
0
To assess the impact on the lipid metabolism, changes in the following parameters were analyzed: total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides.
Query!
Timepoint [9]
0
0
At Year 1, Year 2 and Year 3
Query!
Secondary outcome [10]
0
0
Change in Treatment Satisfaction
Query!
Assessment method [10]
0
0
The change in HIV treatment satisfaction was assessed with the help of the HIV Treatment Satisfaction questionnaire (HIVTSQs), which is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility, etc. HIV TSQs total score: unweighted sum of 10 items of the HIV TSQs (range: 0-60; with higher scores indicating greater treatment satisfaction).
Query!
Timepoint [10]
0
0
At Year 1, Year 2 and Year 3
Query!
Secondary outcome [11]
0
0
Change in Symptom Distress
Query!
Assessment method [11]
0
0
The change in HIV symptom distress was assessed with the help of the HIV Symptom Distress Module (SDM); which is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. SDM total score: unweighted sum of the 20 items (using a 5-point scale, ranging from 0-4), ranging from 0 to 80. Higher scores indicate higher degrees of symptom distress.
Query!
Timepoint [11]
0
0
At Year 1, Year 2 and Year 3
Query!
Secondary outcome [12]
0
0
Number of Participants by Reasons for Therapy Switch to JULUCA
Query!
Assessment method [12]
0
0
The primary and secondary reasons for therapy switch were presented.
Query!
Timepoint [12]
0
0
At Baseline (Day 1)
Query!
Eligibility
Key inclusion criteria
* Greated than or equal to (>=)18 years of age.
* Documented HIV-1 infection.
* Virologically suppressed (HIV-1 ribonucleic acid [RNA] less than [<] 50 copies [c]/mL for at least 6 months)
* Prescription for JULUCA was issued independently from entering this study.
* Ability to understand informed consent form and other relevant study documents
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any contraindication according to JULUCA SmPC.
* Documented viral load greater than (>) 50 c/mL at any time point within 6 months prior to inclusion into this study.
* History of treatment failure.
* Known or suspected substitutions associated with resistance to any non-nucleoside reverse-transcriptase inhibitors (NNRTI) or integrase strand transfer inhibitor (INSTI).
* Any ART for the treatment of HIV-1 in addition to JULUCA.
* Hepatitis B virus (HBV)-co-infection.
* Current participation in the ongoing non-interventional study TRIUMPH (study number: 202033) or any interventional clinical trial irrespective of indication.
* Previous participation in clinical trials involving JULUCA.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/06/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/05/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
209
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Germany
Query!
State/province [1]
0
0
Aachen
Query!
Country [2]
0
0
Germany
Query!
State/province [2]
0
0
Berlin
Query!
Country [3]
0
0
Germany
Query!
State/province [3]
0
0
Bochum
Query!
Country [4]
0
0
Germany
Query!
State/province [4]
0
0
Chemnitz
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Essen
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Hamburg
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Koeln
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Muenchen
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Muenster
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Osnabrueck
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Tuebingen
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Weimar
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
ViiV Healthcare
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
MUC Research GmbH
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a prospective, non-interventional, single-arm, multi-center study aimed at gathering real-world data on JULUCA use in routine clinical care in Germany, to supplement clinical trial data to further improve/optimize care in HIV positive participants in Germany. Approximately 250 virologically suppressed HIV positive participants on stable antiretroviral therapy (ART) were included in the study at the discretion of treating physician. Eligible participants were followed up for approximately 3 years and data was collected during routine clinical care.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03518060
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
ViiV Healthcare
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/60/NCT03518060/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/60/NCT03518060/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03518060
Download to PDF